Univariate | Multivariable-adjusted (model 1)** | Multivariable-adjusted (model 2)** | ||||
---|---|---|---|---|---|---|
HR (95 % CI) | P value | HR (95 % CI) | P value | HR (95 % CI) | P value | |
Age (in years) | ||||||
65 to <75 | Ref | Ref | Ref | |||
75 to <85 | 1.45 (1.29,1.62) | <0.0001 | 1.36 (1.21, 1.52) | <0.0001 | 1.36 (1.21, 1.52) | <0.0001 |
≥85 | 2.08 (1.81, 2.38) | <0.0001 | 1.92 (1.67, 2.21) | <0.0001 | 1.92 (1.67, 2.21) | <0.0001 |
Gender | ||||||
Male | Ref | Ref | Ref | |||
Female | 0.96 (0.87, 1.06) | 0.46 | 0.87 (0.79, 0.96) | 0.007 | 0.87 (0.79, 0.96) | 0.007 |
Race | ||||||
White | Ref | Ref | Ref | |||
Black | 1.18 (1.02, 1.37) | 0.02 | 1.14 (0.98, 1.32) | 0.09 | 1.13 (0.97, 1.31) | 0.11 |
Other | 0.93 (0.78, 1.12) | 0.45 | 0.93 (0.77, 1.11) | 0.41 | 0.92 (0.77, 1.11) | 0.37 |
Charlson- Romano index score | 1.15 (1.14, 1.17) | <0.0001 | 1.15 (1.13, 1.16) | <0.0001 | 1.15 (1.13, 1.16) | <0.0001 |
Statins | 0.86 (0.66, 1.11) | 0.23 | 0.85 (0.66, 1.11) | 0.23 | 0.85 (0.65, 1.11) | 0.22 |
Beta blockers | 1.05 (0.82, 1.33) | 0.72 | 1.02 (0.79, 1.31) | 0.90 | 1.01 (0.79, 1.31) | 0.91 |
Diuretics | 0.92 (0.73, 1.17) | 0.51 | 0.84 (0.66, 1.08) | 0.18 | 0.84 (0.66, 1.08) | 0.17 |
ACE inhibitors | 1.33 (1.03, 1.70) | 0.03 | 1.51 (1.17, 1.95) | 0.002 | 1.51 (1.16, 1.95) | 0.002 |
Allopurinol use | 0.88 (0.79, 0.99) | 0.02 | 0.85 (0.77, 0.95) | 0.004 | - | - |
Allopurinol use duration | ||||||
0 days | Ref | - | - | Ref | ||
1–180 days | 1.00 (0.86, 1.16) | 0.99 | - | - | 0.98 (0.84, 1.14) | 0.76 |
181 days to 2 years | 0.87 (0.76, 1.01) | 0.06 | - | - | 0.83 (0.72, 0.95) | 0.009 |
>2 years | 0.71 (0.56, 0.89) | 0.003 | - | - | 0.70 (0.56, 0.88) | 0.002 |